Perspective Therapeutics reported disease control in 75% of patients at 3.0 mCi, with no serious treatment-related events across 3 dose groups. Only 1 of 2 confirmed responders remained on study around 40 weeks, but the early disease-control and safety results support a positive read.
For CATX, the results offer early evidence that VMT01 may control advanced melanoma without serious treatment-related harm. The small study and limited follow-up temper that read: only 1 of 2 confirmed responders remained on study around 40 weeks.
Follow Perspective Therapeutics, Inc. (CATX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CATX